ADGI ADAGIO THERAPEUTICS INC

Adagio Therapeutics to Participate in Upcoming Investor Conferences

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:

  • Morgan Stanley 20th Annual Global Healthcare Conference: Management will participate in a fireside chat on Monday, September 12, 2022, at 2:50 p.m. ET.



  • H.C. Wainwright 24th Annual Global Investment Conference: Management will participate in 1 on 1 meetings on Tuesday, September 13, 2022.

A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the presentations.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. The company is advancing proprietary antibodies targeting distinct sites with activity against all SARS-CoV-2 variants of concern to date and plans to take a combination of these antibodies into clinical trials in the first quarter of 2023. Beyond COVID-19, Adagio is leveraging its antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit

Contacts

Media Contact:

Tony Berry, Evoke Canale

774-317-0422

Investor Contact:

Chris Brinzey, ICR Westwicke

339-970-2843



EN
06/09/2022

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivi...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG variant appears to be driving a growing wave of COVID-19 in AmericaVYD2311 in vitro neutralization data demonstrate similarly consistent and highly potent results against XFGSimilar new, positive in vitro neutralization data for pemivibart and VYD...

19h / 3m 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Reports Second Quarter 2025 Financial Results and Recent Busin...

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus seasonAnnounced alignment with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody candidate VYD2311 to protect American adults and adolescents from COVID-19Announced attractive safety profile and pharmacokinetics data for VYD23...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) o...

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction in symptomatic COVID-19, resembling CANOPY Cohort BCompany’s target product profile is low-dose, intramuscular, scalable, low-cost, long-lasting, protective option for target populations, including ad...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Mon...

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The SPEAR Study Group was earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines...

July 23, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Mo...

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populationsReflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch